(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 February 2010 (11.02.2010)

PCT

(10) International Publication Number
WO 2010/017070 A1

(51) International Patent Classification:
C07K 16/26 (2006.01) *A61K 39/395* (2006.01)
G01N 33/577 (2006.01) *A61P 7/06* (2006.01)

(21) International Application Number:
PCT/US2009/052044

(22) International Filing Date:
29 July 2009 (29.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/086,557 6 August 2008 (06.08.2008) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Eli Lilly And Company, Lilly Corporate Company, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LEUNG, Donmienne, Doen, Mun** [AU/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **LUAN, Peng** [CN/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **TANG, Ying** [CN/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **WITCHER, Derrick, Ryan** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **YACHI, Pia, Pauliina** [FI/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(74) Agents: **SHARP, Robert, L.** et al.; Eli Lilly And Company, Patent Division, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF




Figure 5

(57) Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.

WO 2010/017070 A1

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*